Search Results - "PARK, Ben H"

Circulating tumor DNA: current challenges for clinical utility by Dang, Donna K, Park, Ben H

“…Cancer cells shed naked DNA molecules into the circulation. This circulating tumor DNA (ctDNA) has become the predominant analyte for liquid biopsies to…”
Get full text

PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients by LOTAN, Tamara L, GUREL, Bora, HAN, Misop, NETTO, George J, ISAACS, William B, DE MARZO, Angelo M, SUTCLIFFE, Siobhan, ESOPI, David, WENNUAN LIU, JIANFENG XU, HICKS, Jessica L, PARK, Ben H, HUMPHREYS, Elizabeth, PARTIN, Alan W

“…Analytically validated assays to interrogate biomarker status in clinical samples are crucial for personalized medicine. PTEN is a tumor suppressor commonly…”
Get full text

Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women by Colak, Dilek, Nofal, Asmaa, Albakheet, Albandary, Nirmal, Maimoona, Jeprel, Hatim, Eldali, Abdelmoneim, Al-Tweigeri, Taher, Tulbah, Asma, Ajarim, Dahish, Malik, Osama Al, Inan, Mehmet S, Kaya, Namik, Park, Ben H, Bin Amer, Suad M

“…Breast cancer in young women is more aggressive with a poorer prognosis and overall survival compared to older women diagnosed with the disease. Despite recent…”
Get full text

Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood by HIGGINS, Michaela J, JELOVAC, Danijela, EMENS, Leisha, RILEY, Carol, STEARNS, Vered, DIEHL, Frank, ANGENENDT, Philipp, PENG HUANG, COPE, Leslie, ARGANI, Pedram, MURPHY, Kathleen M, BACHMAN, Kurtis E, BARNATHAN, Evan, GRESHOCK, Joel, WOLFF, Antonio C, PARK, Ben H, BLAIR, Brian, SLATER, Shannon, POWERS, Penny, ZORZI, Jane, JETER, Stacie C, OLIVER, George R, FETTING, John

“…We sought to evaluate the feasibility of detecting PIK3CA mutations in circulating tumor DNA (ctDNA) from plasma of patients with metastatic breast cancer…”
Get full text

Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease by Wong, Hong Yuen, Sheng, Quanhu, Hesterberg, Amanda B., Croessmann, Sarah, Rios, Brenda L., Giri, Khem, Jackson, Jorgen, Miranda, Adam X., Watkins, Evan, Schaffer, Kerry R., Donahue, Meredith, Winkler, Elizabeth, Penson, David F., Smith, Joseph A., Herrell, S. Duke, Luckenbaugh, Amy N., Barocas, Daniel A., Kim, Young J., Graves, Diana, Giannico, Giovanna A., Rathmell, Jeffrey C., Park, Ben H., Gordetsky, Jennifer B., Hurley, Paula J.

“…Cribriform prostate cancer, found in both invasive cribriform carcinoma (ICC) and intraductal carcinoma (IDC), is an aggressive histological subtype that is…”
Get full text

The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer by Beaver, Julia A, Park, Ben H

“…The combination of the mTOR inhibitor everolimus with the aromatase inhibitor exemestane was evaluated in the randomized Phase III BOLERO-2 trial. Research has…”
Get more information

Genomic dissection and mutation-specific target discovery for breast cancer PIK3CA hotspot mutations by Miranda, Adam X, Kemp, Justin, Davidson, Brad A, Bellomo, Sara Erika, Miranda, Verda E, Manoni, Alexandra, Marchiò, Caterina, Croessmann, Sarah, Park, Ben H, Hodges, Emily

“…Recent advancements in high-throughput genomics and targeted therapies have provided tremendous potential to identify and therapeutically target distinct…”
Get full text

Single-cell analysis of somatic mutation burden in mammary epithelial cells of pathogenic BRCA1/2 mutation carriers by Sun, Shixiang, Brazhnik, Kristina, Lee, Moonsook, Maslov, Alexander Y, Zhang, Yi, Huang, Zhenqiu, Klugman, Susan, Park, Ben H, Vijg, Jan, Montagna, Cristina

“…Inherited germline mutations in the breast cancer gene 1 (BRCA1) or BRCA2 genes (herein BRCA1/2) greatly increase the risk of breast and ovarian cancer,…”
Get full text

Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression by Hughes, Robert M, Simons, Brian W, Khan, Hamda, Miller, Rebecca, Kugler, Valentina, Torquato, Samantha, Theodros, Debebe, Haffner, Michael C, Lotan, Tamara, Huang, Jessie, Davicioni, Elai, An, Steven S, Riddle, Ryan C, Thorek, Daniel L J, Garraway, Isla P, Fertig, Elana J, Isaacs, John T, Brennen, W Nathaniel, Park, Ben H, Hurley, Paula J

“…Tumor progression to metastasis is not cancer cell autonomous, but rather involves the interplay of multiple cell types within the tumor microenvironment. Here…”
Get full text

Systemic inhibition of PTPN22 augments anticancer immunity by Ho, Won Jin, Croessmann, Sarah, Lin, Jianping, Phyo, Zaw H, Charmsaz, Soren, Danilova, Ludmila, Mohan, Aditya A, Gross, Nicole E, Chen, Fangluo, Dong, Jiajun, Aggarwal, Devesh, Bai, Yunpeng, Wang, Janey, He, Jing, Leatherman, James M, Yarchoan, Mark, Armstrong, Todd D, Zaidi, Neeha, Fertig, Elana J, Denny, Joshua C, Park, Ben H, Zhang, Zhong-Yin, Jaffee, Elizabeth M

“…Both epidemiologic and cellular studies in the context of autoimmune diseases have established that protein tyrosine phosphatase non-receptor type 22 (PTPN22)…”
Get full text

The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer by Davidson, Brad A., Croessmann, Sarah, Park, Ben H.

“…Advances in genomic strategies and the development of targeted therapies have enabled precision medicine to revolutionise the field of oncology. Precision…”
Get full text

Male breast cancer: a disease distinct from female breast cancer by Gucalp, Ayca, Traina, Tiffany A., Eisner, Joel R., Parker, Joel S., Selitsky, Sara R., Park, Ben H., Elias, Anthony D., Baskin-Bey, Edwina S., Cardoso, Fatima

“…Purpose Male breast cancer (BC) is rare, representing approximately 1% of cancers that occur in men and approximately 1% of all BCs worldwide. Because male BC…”
Get full text

Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity by Christenson, Eric S., James, Theodore, Agrawal, Vineet, Park, Ben H.

“…To review the evidence for the use of various biomarkers in the detection of chemotherapy associated cardiac damage. Pubmed.gov was queried using the search…”
Get full text

A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers by Jelovac, Danijela, MD, Beaver, Julia A., MD, Balukrishna, Sasidharan, MD, Wong, Hong Yuen, BS, Toro, Patricia Valda, BS, Cimino-Mathews, Ashley, MD, Argani, Pedram, MD, Stearns, Vered, MD, Jacobs, Lisa, MD, VanDenBerg, Dustin, BS, Kessler, Jill, BS, Jeter, Stacie, BS, Park, Ben H., MD, PhD, Wolff, Antonio C., MD

“…Summary Digital polymerase chain reaction is a new technology that enables detection and quantification of cancer DNA molecules from peripheral blood. Using…”
Get full text

Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old by Colak, Dilek, Chishti, Muhammad A, Al-Bakheet, Al-Bandary, Al-Qahtani, Ahmed, Shoukri, Mohamed M, Goyns, Malcolm H, Ozand, Pinar T, Quackenbush, John, Park, Ben H, Kaya, Namik

“…Hepatocellular carcinoma (HCC) is the third-leading cause of cancer-related deaths worldwide. It is often diagnosed at an advanced stage, and hence typically…”
Get full text

Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131 by Mayer, Ingrid A, Zhao, Fengmin, Arteaga, Carlos L, Symmans, William F, Park, Ben H, Burnette, Brian L, Tevaarwerk, Amye J, Garcia, Sofia F, Smith, Karen L, Makower, Della F, Block, Margaret, Morley, Kimberly A, Jani, Chirag R, Mescher, Craig, Dewani, Shabana J, Tawfik, Bernard, Flaum, Lisa E, Mayer, Erica L, Sikov, William M, Rodler, Eve T, Wagner, Lynne I, DeMichele, Angela M, Sparano, Joseph A, Wolff, Antonio C, Miller, Kathy D

“…Patients with triple-negative breast cancer (TNBC) and residual invasive disease (RD) after completion of neoadjuvant chemotherapy (NAC) have a high-risk for…”
Get full text

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer by De Angelis, Carmine, Fu, Xiaoyong, Cataldo, Maria Letizia, Nardone, Agostina, Pereira, Resel, Veeraraghavan, Jamunarani, Nanda, Sarmistha, Qin, Lanfang, Sethunath, Vidyalakshmi, Wang, Tao, Hilsenbeck, Susan G, Benelli, Matteo, Migliaccio, Ilenia, Guarducci, Cristina, Malorni, Luca, Litchfield, Lacey M, Liu, Jiangang, Donaldson, Joshua, Selenica, Pier, Brown, David N, Weigelt, Britta, Reis-Filho, Jorge S, Park, Ben H, Hurvitz, Sara A, Slamon, Dennis J, Rimawi, Mothaffar F, Jansen, Valerie M, Jeselsohn, Rinath, Osborne, C Kent, Schiff, Rachel

“…Cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (CDK4/6i) are highly effective against estrogen receptor-positive (ER )/HER2 breast cancer; however,…”
Get full text

Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis by Li, Zheqi, Wu, Yang, Yates, Megan E, Tasdemir, Nilgun, Bahreini, Amir, Chen, Jian, Levine, Kevin M, Priedigkeit, Nolan M, Nasrazadani, Azadeh, Ali, Simak, Buluwela, Laki, Arnesen, Spencer, Gertz, Jason, Richer, Jennifer K, Troness, Benjamin, El-Ashry, Dorraya, Zhang, Qiang, Gerratana, Lorenzo, Zhang, Youbin, Cristofanilli, Massimo, Montanez, Maritza A, Sundd, Prithu, Wallace, Callen T, Watkins, Simon C, Fumagalli, Caterina, Guerini-Rocco, Elena, Zhu, Li, Tseng, George C, Wagle, Nikhil, Carroll, Jason S, Jank, Paul, Denkert, Carsten, Karsten, Maria M, Blohmer, Jens-Uwe, Park, Ben H, Lucas, Peter C, Atkinson, Jennifer M, Lee, Adrian V, Oesterreich, Steffi

“…Constitutively active estrogen receptor α (ER/ESR1) mutations have been identified in approximately one-third of ER+ metastatic breast cancers. Although these…”
Get full text

Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer by Connolly, Roisin M, Leal, Jeffrey P, Solnes, Lilja, Huang, Chiung-Yu, Carpenter, Ashley, Gaffney, Katy, Abramson, Vandana, Carey, Lisa A, Liu, Minetta C, Rimawi, Mothaffar, Specht, Jennifer, Storniolo, Anna Maria, Valero, Vicente, Vaklavas, Christos, Krop, Ian E, Winer, Eric P, Camp, Melissa, Miller, Robert S, Wolff, Antonio C, Cimino-Mathews, Ashley, Park, Ben H, Wahl, Richard L, Stearns, Vered

“…Predictive biomarkers to identify patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer who may benefit from targeted therapy…”
Get full text

Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy-Induced Necrosis by Ghosh, Santanu, Yang, Rachel, Duraki, Darjan, Zhu, Junyao, Kim, Ji Eun, Jabeen, Musarrat, Mao, Chengjian, Dai, Xinyi, Livezey, Mara R, Boudreau, Matthew W, Park, Ben H, Nelson, Erik R, Hergenrother, Paul J, Shapiro, David J

“…Several emerging therapies kill cancer cells primarily by inducing necrosis. As necrosis activates immune cells, potentially, uncovering the molecular drivers…”
Get full text